ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1095

Periarticular Bone Loss in Arthritis Is Induced By Autoantibodies Against Citrullinated Vimentin

Cecilia Engdahl1, Holger Bang2, Katharina Dietel1, Stefanie C Lang1, Ulrike Harre1 and Georg Schett3, 1Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany, 2Orgentec Diagnostics, Mainz, Germany, 3Department of Internal Medicine III, Institute for Clinical Immunology,, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Auto-immunity, autoantibodies and bone density, Early Rheumatoid Arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Biology and Pathology of Bone and Joint - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Periarticular bone loss is a long known and early but yet insufficiently understood phenomenon in patients with rheumatoid arthritis. This study investigated whether autoimmunity against citrullinated proteins is causally involved in triggering focal trabecular bone loss by modifying a standard experimental model of periarticular bone loss in the context of arthritis.

Methods: Antigen induced arthritis (AIA) was induced by methylated bovine serum albumin (mBSA) and modified by mutated citrullinated vimentin (MCV). Periarticular bone loss, subchondral osteoclastogenesis as well as expression of PAD enzyme, bone associated genes and cytokines, were assessed after arthritis induction. Immune cell and osteoclast precursor infiltration were detected in the periarticular bone marrow and the local lymph nodes. In addition, periarticular bone loss was assessed upon challenge of mice with anti-MCV antibodies.

Results: Despite inducing a milder form of arthritis than mBSA, MCV triggered significant periarticular bone loss associated with an increased infiltration of osteoclast precursors and mature osteoclasts in the periarticular bone marrow. MCV enhanced the expression of the osteoclast inducers RANKL and MCSF, the cytokines IL-8, IL-1, IL-6 and TNF-α as well as PAD2 and PAD4 enzymes in the focal bone marrow. In addition, also anti-MCV antibody challenge induced significant periarticular bone loss and osteoclastogenesis in the bone marrow of mice.

Conclusion: Autoimmunity against citrullinated vimentin triggers periarticular bone loss by osteoclast activation in the bone marrow. These findings may explain why periarticular bone loss is already found very early in the disease course of rheumatoid arthritis patients.


Disclosure: C. Engdahl, None; H. Bang, Orgentec Diagnostika, 3; K. Dietel, None; S. C. Lang, None; U. Harre, None; G. Schett, None.

To cite this abstract in AMA style:

Engdahl C, Bang H, Dietel K, Lang SC, Harre U, Schett G. Periarticular Bone Loss in Arthritis Is Induced By Autoantibodies Against Citrullinated Vimentin [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/periarticular-bone-loss-in-arthritis-is-induced-by-autoantibodies-against-citrullinated-vimentin/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/periarticular-bone-loss-in-arthritis-is-induced-by-autoantibodies-against-citrullinated-vimentin/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology